"RIV/00216208:11160/12:10124217!RIV13-MSM-11160___" . "[74E56B1939FF]" . . "Background: Hyaluronan (HYA) is a high molecular weight glucosaminoglycan with a great perspective for medical applications. Because HYA is widespread in the body, it is difficult to determine the fate of exogenously administered HYA. Methods: In this study, HYA of different molecular weights (0.1-1 MDa) was labelled with Tc-99m, and the distribution profiles were determined after administrating the HYA to rats. Results: After the intravenous administration of Tc-99m-HYA, a rapid decrease in the radioactivity of blood samples was observed, presumably because of Tc-99m-HYA uptake by the liver; only minimal signs of liver radioactivity washout were detected. After the oral administration of Tc-99m-HYA, no significant absorption to the central compartment was found. A preliminary study using C-14-HYA exhibited a different distribution profile than Tc-99m-HYA because of the different administered dose and the fate of the degradation products. Even with C-14-HYA, only traces of radioactivity were absorbed after oral administration. Conclusion: This paper provides quantitative information regarding the distribution parameters of radiolabelled HYA in preclinical experiments."@en . "L\u00E1zn\u00ED\u010Dkov\u00E1, Alice" . "64" . "L\u00E1zn\u00ED\u010Dek, Milan" . . . "RIV/00216208:11160/12:10124217" . "\u010Co\u017E\u00EDkov\u00E1, Dagmar" . "2" . "PL - Polsk\u00E1 republika" . "http://rabbit.if-pan.krakow.pl/pjp/pdf/2012/2_428.pdf" . . . . "Background: Hyaluronan (HYA) is a high molecular weight glucosaminoglycan with a great perspective for medical applications. Because HYA is widespread in the body, it is difficult to determine the fate of exogenously administered HYA. Methods: In this study, HYA of different molecular weights (0.1-1 MDa) was labelled with Tc-99m, and the distribution profiles were determined after administrating the HYA to rats. Results: After the intravenous administration of Tc-99m-HYA, a rapid decrease in the radioactivity of blood samples was observed, presumably because of Tc-99m-HYA uptake by the liver; only minimal signs of liver radioactivity washout were detected. After the oral administration of Tc-99m-HYA, no significant absorption to the central compartment was found. A preliminary study using C-14-HYA exhibited a different distribution profile than Tc-99m-HYA because of the different administered dose and the fate of the degradation products. Even with C-14-HYA, only traces of radioactivity were absorbed after oral administration. Conclusion: This paper provides quantitative information regarding the distribution parameters of radiolabelled HYA in preclinical experiments." . "pharmacokinetics; biodistribution; radiolabelling; Tc-99m; C-14; hyaluronan"@en . . . "10"^^ . "11160" . . "1734-1140" . . "Pharmacological Reports" . "Preclinical pharmacokinetics of radiolabelled hyaluronan"@en . "160958" . . . "3"^^ . "000305546700023" . "Preclinical pharmacokinetics of radiolabelled hyaluronan" . . "Preclinical pharmacokinetics of radiolabelled hyaluronan"@en . . "Preclinical pharmacokinetics of radiolabelled hyaluronan" . "Velebny, Vladimir" . . . . . . "I" . "4"^^ . .